732.87

0.62% -4.58

Regeneron Pharmaceuticals Inc (REGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché REGN Giù? Forum Previsione

Precedente Chiudi:

$737.45

Aprire:

$738.17

Volume 24 ore:

1.36M

Relative Volume:

1.75

Capitalizzazione di mercato:

$77.48B

Reddito:

$14.34B

Utile/perdita netta:

$4.50B

Rapporto P/E:

17.63

EPS:

41.5626

Flusso di cassa netto:

$3.77B

1 W Prestazione:

-1.73%

1M Prestazione:

-6.00%

6M Prestazione:

+23.80%

1 anno Prestazione:

+10.60%

Intervallo 1D:

$728.64

$744.85

Intervallo di 1 settimana:

$727.88

$771.23

Portata 52W:

$476.49

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Nome

Regeneron Pharmaceuticals Inc

Settore

Healthcare (1110)

Industria

Biotechnology (621)

Telefono

(914) 847-7000

Indirizzo

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Dipendente

15,410

Cinguettio

@regeneron

Prossima data di guadagno

2026-01-30

Ultimi documenti SEC

REGN's Discussions on Twitter

Compare REGN vs VRTX, ALNY, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
REGN Regeneron Pharmaceuticals Inc	732.87	77.48B	14.34B	4.50B	3.77B	41.56
VRTX Vertex Pharmaceuticals Inc	454.00	115.33B	12.07B	3.95B	3.19B	15.33
ALNY Alnylam Pharmaceuticals Inc	312.17	41.40B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	663.93	41.09B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	275.28	30.56B	5.36B	287.73M	924.18M	2.5229

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-06	Iniziato	Barclays	Overweight
2026-01-07	Aggiornamento	BofA Securities	Underperform → Buy
2025-12-03	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Iniziato	HSBC Securities	Buy
2025-11-24	Ripresa	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Perform
2025-08-14	Iniziato	Rothschild & Co Redburn	Buy
2025-06-30	Downgrade	Argus	Buy → Hold
2025-05-30	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-05-14	Aggiornamento	Citigroup	Neutral → Buy
2025-04-22	Ripresa	Cantor Fitzgerald	Overweight
2025-02-05	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-01-16	Downgrade	UBS	Buy → Neutral
2024-12-10	Ripresa	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Neutral
2024-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-12	Iniziato	Bernstein	Outperform
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Ripresa	Wells Fargo	Overweight
2021-12-07	Ripresa	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Ripresa	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Ripresa	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

Mar 21, 2026

Why Regeneron Pharmaceuticals (REGN) is one of the top gene therapy stocks to buy according to hedge funds - MSN

Mar 21, 2026

Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN) - The Globe and Mail

Mar 21, 2026

Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 21, 2026

Is It Time To Revisit Regeneron (REGN) After Recent Share Price Pullback? - simplywall.st

Mar 21, 2026

Swiss Life Asset Management Ltd Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 21, 2026

Mar 20, 2026

BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $860 - Moomoo

Mar 20, 2026

PCSK9 Inhibitor Market to Reach US$7.67 Billion by 2033 at 16.5% - openPR.com

Mar 20, 2026

Mar 19, 2026

Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie - Barchart.com

Mar 19, 2026

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail

Mar 19, 2026

Formycon secures license date for aflibercept biosimilar FYB203 in Europe - The Pharma Letter

Mar 19, 2026

Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 19, 2026

Groupama Asset Managment Sells 5,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 19, 2026

Mar 18, 2026

Lower LDL Is Better In New ACC/AHA Guidelines, Making The Case For Add-Ons To Statins - Citeline News & Insights

Mar 18, 2026

Trading Action: What are the future prospects of Regeneron Pharmaceuticals Inc2026 Volume Leaders & AI Driven Stock Reports - baoquankhu1.vn

Mar 18, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Mar 18, 2026

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed On Friday - MSN

Mar 18, 2026

Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN

Mar 18, 2026

Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? - MSN

Mar 18, 2026

Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN

Mar 18, 2026

Caerus Investment Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 18, 2026

Mar 17, 2026

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.

Mar 17, 2026

BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD - The Globe and Mail

Mar 17, 2026

Regeneron: EPS Set to Jump 18% in 2027 as Obesity Bet Reframes the Investment Case - TIKR.com

Mar 17, 2026

Holocene Advisors LP Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

Brevan Howard Capital Management LP Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

California Public Employees Retirement System Sells 111,602 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

Boothbay Fund Management LLC Buys 1,541 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

Mar 16, 2026

Behavioral Patterns of REGN and Institutional Flows - Stock Traders Daily

Mar 16, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 16, 2026

Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease - TipRanks

Mar 16, 2026

Hamilton Wealth LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 16, 2026

Gotham Asset Management LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 16, 2026